

## Drug Monograph

Drug/Drug     **Aptensio XR™ (methylphenidate hydrochloride)**  
Class:         **extended-release capsule / ADHD**  
Prepared for: MO HealthNet  
Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
<b>Dosage Forms:</b>	Aptensio XR™ is available in extended-release capsules containing 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, or 60 mg of methylphenidate hydrochloride respectively.
<b>Manufacturer:</b>	Patheon Manufacturing Services LLC, Greenville, NC 27834
<b>Indications:</b>	Aptensio XR™ is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
<b>Costs:</b>	\$6.50 per capsule of all strengths of Aptensio XR™. Wholesale Acquisition Cost
<b>Summary of Findings:</b>	The Division recommends adding this drug to the current ADHD clinical edit.
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> Clinical Edit
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Non-Preferred Agent <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer, Pharm. D.  
Date: August 4, 2015